MNPR 8-K SEC Filing Analysis

Latest settled — T+20d ⚠ clustered

MNPR ▲ +2.83% at T+20d

LONG call ✓ call won +2.83% · α vs SPY -1.37% · entry $54.70 → $56.25

Next anchor: T+60d in 7w

Last close $63.12 (close May 22) · +15.39% from $54.70 entry

Entry anchored
Apr 17, 03:59 PM ET
via Databento tick

T+1d

-3.64%

call -3.64% · α -2.98%

$52.71

settled 5w ago

T+5d

-1.24%

call -1.24% · α -2.16%

$54.02

settled 27d ago

T+20d

+2.83%

call +2.83% · α -1.37%

$56.25

settled 6d ago

T+60d

—

call — · α —

—

in 7w

Price Chart

Loading chart...

Executive Summary

Monopar Therapeutics announced positive Phase 3 clinical trial data showing ALXN1840 demonstrated greater neurologic benefit versus standard of care in Wilson disease patients with neurologic symptoms. The data supports the planned New Drug Application submission to the FDA in mid-2026.

Actionable Insight

The positive Phase 3 data significantly de-risks the ALXN1840 program and increases the probability of FDA approval. This could lead to substantial revenue growth if approved, making this a key catalyst for the stock. Monitor for upcoming regulatory interactions with FDA.

Key Facts

New Phase 3 data shows ALXN1840 provided greater neurologic improvement and significantly less worsening than standard of care in Wilson disease patients
Data presented at American Academy of Neurology (AAN) Annual Meeting 2026
Findings support planned New Drug Application (NDA) submission to FDA in mid-2026
ALXN1840 has favorable safety profile with drug-related serious adverse events limited to 4.9% of patients

Financial Impact

Potential approval and commercialization of ALXN1840 for Wilson disease

revenuedrug development pipeline

Risk Factors

Regulatory approval is not guaranteed
Potential competition from other Wilson disease treatments
Clinical trial results may not translate to real-world effectiveness

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

Document	Accession Number
8-K Filing (Primary)	0001437749-26-012751
Exhibit: ex_947617.htm	0001437749-26-012751
Document: 0001437749-26-012751-index-headers.html	0001437749-26-012751
Document: 0001437749-26-012751-index.html	0001437749-26-012751
Document: 0001437749-26-012751.txt	0001437749-26-012751

6 reports for MNPR

T+1T+5T+20T+60

Track record builds as more directional reports settle.

Filters

Reports for MNPR — sortable, filterable
	Type				Now
May 19, 2026 4d ago	8-K BULLISH ★ 6/10	—	awaiting T+20	—	—
May 14, 2026 9d ago	8-K NEUTRAL ★ 4/10	$60.78 awaiting T+20	awaiting T+20	—	$63.12 (+3.85%)
May 14, 2026 9d ago	Press Release BULLISH ★ 6/10	$59.15 awaiting T+20	awaiting T+20	—	$63.12 (+6.71%)
Apr 20, 2026 4w ago	8-K BULLISH ★ 7/10	$54.70 $56.25	▲ +2.83%	▼ −1.37%	$63.12 (+15.39%)
Apr 19, 2026 4w ago	Press Release BULLISH ★ 8/10	$54.70 $56.25	▲ +2.83%	▼ −1.37%	$63.12 (+15.39%)
Mar 27, 2026 8w ago	Press Release BULLISH ★ 7/10	$54.10 $54.02	▼ −0.15%	▼ −12.89%	$63.12 (+16.67%)

US Market Status

Market Closed — Opens Tue (35h 15m)

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access